Correction to: A strategy for the convergent and stereoselective assembly of polycyclic molecules (Journal of the American Chemical Society (2018) 140 (1956-1965) DOI: 10.1021/jacs.7b13234)

Pages 1960-1961. It has come to our attention that there is an error in the compound concentrations employed for the cytotoxicity assays. The cell viability studies for newly synthesized compounds were conducted at 1 mM rather than 1 μM, and the updated version Table 1 herein reflects this correction. Therefore, the correct IC₅₀ values for bisepoxide 32 are 200 μM against MDA-MB-231-LM24 cells and 3100 μM against non-tumorigenic MCF10A cells. (Table Presented). This realization alters the interpretation of these preliminary assay results, as the actual loaded concentrations are much higher, and as such, the compounds are considerably less promising as novel cytotoxic agents for further study. The relative discussion of comparative activity among the compounds as was published remains appropriate. The results establish a distinct difference in activity between those compounds containing enone functionality and their saturated counterparts. However, as the quantitative activity is 1000 times less than was originally reported, significant investigation would be required to obtain relevant levels of potency. The positive control using doxorubicin has been removed from the corrected Table 1, since the original values for this control were correctly determined at 1.0 ?M, making the comparison meaningless. The corrected version of Table 1 is presented herein, and the concentrations have been properly adjusted in the Supporting Information on pages S34-S35.